%0 Journal Article %A IOANNIS PAPASOTIRIOU %A GEORGIOS BEIS %A AGGELOS C. ILIOPOULOS %A PANAGIOTIS APOSTOLOU %T Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer: A Preliminary Study %D 2022 %R 10.21873/invivo.12779 %J In Vivo %P 898-906 %V 36 %N 2 %X Background/Aim: An early evaluation concerning the effectiveness of supportive oligonucleotide therapy (SOT) in cancer as a monotherapy and in combination with other types of treatment. Patients and Methods: This study evaluated the clinical condition and performance status (Karnofsky-Index) of 95 patients, post-SOT administration. Furthermore, circulating tumor cells (CTCs) from 47 patients’ pre- and post-SOT administration were measured and analyzed by repeated-measures ANOVA. Results: Improvement of the clinical condition was observed in all patients who used SOT (77.89%), SOT in combination with other therapy (69.77%) and SOT as a monotherapy or no information was given concerning another therapy (84.31%). Positive results for Karnofsky-Index were also observed in 71.58%, 61.36%, and 80.39%, respectively. Finally, statistically significant reductions in CTCs were observed for both SOT as a monotherapy and SOT as an adjunctive therapy. Conclusion: The preliminary results indicate that SOT therapy can be used both as monotherapy as well as in combination with other therapies for cancer. %U https://iv.iiarjournals.org/content/invivo/36/2/898.full.pdf